October 21, 2022 02:45 PM EDT
Pharma
Law

Will feds re­clas­si­fy 'mag­ic mush­room' ther­a­pies? Seat­tle doc­tor ramps up court bat­tle

Nicole DeFeudis

Editor

As psy­che­del­ic ther­a­pies make their way through the clin­ic, one Seat­tle doc­tor is tak­ing his fight to change psilo­cy­bin’s sta­tus as a Sched­ule I sub­stance …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­phar­ma be­gins to con­tem­plate an RFK Jr.-in­flu­enced FDA if Trump wins

Pfiz­er shares new de­tails on obe­si­ty pipeline, hints at ‘oth­er op­por­tu­ni­ties’

GSK buys au­toim­mune T cell en­gager for $300M up­front from Chim­a­gen

No­var­tis takes $800M Mor­phoSys write­down mere months af­ter clos­ing ac­qui­si­tion

No­var­tis high­lights over­all M&A track record fol­low­ing Mor­phoSys im­pair­ment

Fol­low­ing March in­spec­tion, No­vo Nordisk's semaglu­tide man­u­fac­tur­ing fa­cil­i­ty cit­ed by FDA

A service from the Financial Times